Advanced search
Publication Cover
Hematology Volume 24, 2019 - Issue 1
Submit an article Journal homepage
3,032
Views
4
CrossRef citations to date
0
Altmetric
Case Report

The clinical outcomes of chronic myeloid leukemia patients harboring alternatively spliced BCR-ABL variants

Takashi IshidaDepartment of Transfusion and Cell Transplantation, Kitasato University School of Medicine, Kanagawa, Japan;Department of Hematology, Kitasato University School of Medicine, Kanagawa, JapanORCID Iconhttps://orcid.org/0000-0002-9429-1763
ORCID Icon,
Koji MiyazakiDepartment of Transfusion and Cell Transplantation, Kitasato University School of Medicine, Kanagawa, Japan
,
Sosei OkinaDepartment of Hematology, Kitasato University School of Medicine, Kanagawa, Japan
,
Tomomi MiyataDepartment of Hematology, Kitasato University School of Medicine, Kanagawa, Japan
,
Kei HayamaDepartment of Hematology, Kitasato University School of Medicine, Kanagawa, Japan
,
Masaaki HigashiharaDepartment of Hematology, Kitasato University School of Medicine, Kanagawa, Japan
&
Takahiro SuzukiDepartment of Hematology, Kitasato University School of Medicine, Kanagawa, JapanCorrespondence[email protected]
 show all
Pages 49-51 | Published online: 20 Aug 2018

References

  • Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355(23):2408–2417. doi: 10.1056/NEJMoa062867
  • O'Hare T, Zabriskie MS, Eide CA, et al. The BCR-ABL35INS insertion/truncation mutant is kinase-inactive and does not contribute to tyrosine kinase inhibitor resistance in chronic myeloid leukemia. Blood. 2011 Nov 10;118(19):5250–5254. doi: 10.1182/blood-2011-05-349191
  • Ma W, Kantarjian H, Yeh C-H, et al. BCR-ABL truncation due to premature translation termination as a mechanism of resistance to kinase inhibitors. Acta Haematol. 2009;121(1):27–31. doi: 10.1159/000210060
  • Laudadio J, Deininger MW, Mauro MJ, et al. An intron-derived insertion/truncation mutation in the BCR-ABL kinase domain in chronic myeloid leukemia patients undergoing kinase inhibitor therapy. J Mol Diagn. 2008 Mar;10(2):177–180. doi: 10.2353/jmoldx.2008.070128
  • Itonaga H, Tsushima H, Imanishi D, et al. Molecular analysis of the BCR-ABL1 kinase domain in chronic-phase chronic myelogenous leukemia treated with tyrosine kinase inhibitors in practice: study by the Nagasaki CML Study Group. Leuk Res. 2014 Jan;38(1):76–83. doi: 10.1016/j.leukres.2013.10.022
  • Meggyesi N, Kalmar L, Fekete S, et al. Characterization of ABL exon 7 deletion by molecular genetic and bioinformatic methods reveals no association with imatinib resistance in chronic myeloid leukemia. Med Oncol. 2012 Sep;29(3):2136–2142. doi: 10.1007/s12032-011-0092-9
  • Marce S, Cortes M, Zamora L, et al. A thirty-five nucleotides BCR-ABL1 insertion mutation of controversial significance confers resistance to imatinib in a patient with chronic myeloid leukemia (CML). Exp Mol Pathol. 2015 Aug;99(1):16–18. doi: 10.1016/j.yexmp.2015.04.007
  • Lee TS, Ma W, Zhang X, et al. BCR-ABL alternative splicing as a common mechanism for imatinib resistance: evidence from molecular dynamics simulations. Mol Cancer Ther. 2008 Dec;7(12):3834–3841. doi: 10.1158/1535-7163.MCT-08-0482
  • Yuda J, Miyamoto T, Odawara J, et al. Persistent detection of alternatively spliced BCR-ABL variant results in a failure to achieve deep molecular response. Cancer Sci. 2017 Nov;108(11):2204–2212. doi: 10.1111/cas.13353
  • Ishida T, Akagawa N, Miyata T, et al. Dasatinib-associated reversible demyelinating peripheral polyneuropathy in a case of chronic myeloid leukemia. Int J Hematol. 2018 Mar;107(3):373–377. doi: 10.1007/s12185-017-2339-5

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.